Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.76
+0.01 (0.02%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Company Description

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome.

The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics, Inc.
Soleno Therapeutics logo
Country United States
Founded 1999
IPO Date Nov 13, 2014
Industry Biotechnology
Sector Healthcare
Employees 182
CEO Anish Bhatnagar

Contact Details

Address:
100 Marine Parkway, Suite 400
Redwood City, California 94065
United States
Phone 650 213 8444
Website soleno.life

Stock Details

Ticker Symbol SLNO
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001484565
CUSIP Number 834203200
ISIN Number US8342033094
Employer ID 77-0523891
SIC Code 2834

Key Executives

Name Position
Dr. Anish Bhatnagar M.D. Chairman, President and Chief Executive Officer
Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs
James H. MacKaness Executive Officer
Meredith Manning M.B.A. Chief Commercial Officer
Jennifer Fulk Chief Financial Officer
Jesse Schumaker General Counsel
Lauren Budesheim Senior Vice President of People
Kristen Yen M.S. Senior Vice President of Global Clinical Operations and Patient Advocacy
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of New Product Planning
Dr. Michael Huang M.D. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
Apr 28, 2026 SC 14D9/A Filing
Apr 28, 2026 SC TO-T/A Filing
Apr 24, 2026 SCHEDULE 13G/A Filing
Apr 20, 2026 SC 14D9 Filing
Apr 20, 2026 SC TO-T Filing
Apr 7, 2026 8-K Current Report
Apr 7, 2026 SC TO-C Filing
Apr 6, 2026 SC14D9C Filing
Apr 6, 2026 SC TO-C Filing
Apr 6, 2026 8-K Current Report